C12N 2760/16251
Methods of production or purification of viral material
C12N2760/16251 (Methods of production or purification of viral material) appears on 112 US grants and 151 published applications in this corpus.
Search patents in C12N- Granted patents
- 112
- Published applications
- 151
- Assignees
- 82
- Inventors
- 230
- Latest grant
- 30 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 2 | 0 |
| 1977 | 0 | 0 |
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 1 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 1 | 0 |
| 1998 | 1 | 0 |
| 1999 | 1 | 0 |
| 2000 | 2 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 0 |
| 2003 | 2 | 2 |
| 2004 | 0 | 2 |
| 2005 | 1 | 3 |
| 2006 | 1 | 4 |
| 2007 | 3 | 5 |
| 2008 | 2 | 7 |
| 2009 | 3 | 8 |
| 2010 | 3 | 14 |
| 2011 | 4 | 7 |
| 2012 | 8 | 12 |
| 2013 | 8 | 11 |
| 2014 | 5 | 6 |
| 2015 | 4 | 7 |
| 2016 | 7 | 12 |
| 2017 | 6 | 9 |
| 2018 | 5 | 7 |
| 2019 | 8 | 5 |
| 2020 | 9 | 12 |
| 2021 | 5 | 3 |
| 2022 | 4 | 7 |
| 2023 | 3 | 2 |
| 2024 | 3 | 4 |
| 2025 | 5 | 1 |
| 2026 | 2 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- MDCK suspension cell lines in serum-free, chemically-defined media for vaccine production30 Jun 2026US 12,667,612 B2Fujifilm Biosciences Inc.
- Method of labelling viral particles comprising anionic lipids with fluorescently-labelled negatively-charged polynucleotides in the presence of polyvalent cations21 Apr 2026US 12,607,635 B2Oxford University Innovation Limited
- Influenza virus-like particle production in plants11 Nov 2025US 12,467,058 B2Aramis Biotechnologies Inc.
- Influenza B virus replication for vaccine development22 Jul 2025US 12,364,748 B2Wisconsin Alumni Research Foundation (WARF)
- Recombinant high growth rate influenza virus comprising mutations in M1, NS2, and PB28 Jul 2025US 12,350,325 B2Bluesky Immunotherapies GmbH
- Influenza b virus replication for vaccine development12 Feb 2026US 2026/0041756 A1Wisconsin Alumni Research Foundation (WARF)
- Modified influenza b hemagglutinin polypeptides and nucleic acids and uses thereof20 Mar 2025US 2025/0090650 A1Sanofi
- Respiratory virus combination vaccines4 Jul 2024US 2024/0216500 A1ModernaTX, Inc.
- Mdck suspension cell lines in serum-free, chemically-defined media for vaccine production11 Apr 2024US 2024/0115690 A1FUJIFILM Irvine Scientific, Inc.
- Downstream process for purification of viral proteins with hydrophobic membrane domain for use in vaccine compositions7 Mar 2024US 2024/0076320 A1Novavax, Inc.
Most cited
By later US patents
- Preservation of bioactive materials by spray drying51US 7,258,873 B2MedImmune Vaccines, Inc. · 2007
- Recombinant influenza vectors with tandem transcription units41US 7,968,101 B2Wisconsin Alumni Research Foundation · 2011
- Methods and interferon deficient substrates for the propagation of viruses37US 6,852,522 B1Mount Sinai School of Medicine of New York University · 2005
- Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals35US 6,669,943 B1Mount Sinai School of Medicine of New York University · 2003
- Methods and interferon deficient substrates for the propagation of viruses34US 6,573,079 B1Mount Sinai School of Medicine of New York University · 2003